Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
It’s been less than a month since EBV returned to the spotlight: almost invisible in the body, it can remain for years without clear signs. Now, a new strategy with laboratory-created antibodies targets the virus’s entry into cells and reignites the debate about preventing serious diseases.
The EBV virus infects about 95% of the world’s population and usually remains hidden in the body after the first contact. In many cases, it goes unnoticed, but it can also be linked to serious diseases when it finds gaps in the immune system.
The new stage of the research is noteworthy because it targets the virus before it can enter cells. Scientists used mice with human genes linked to antibody production to create molecules capable of recognizing specific points of EBV.
The result still does not represent a cure or treatment available in hospitals. Nevertheless, the advance opens a concrete path for future preventive therapies, especially in people at higher risk of complications.
-
Scientists reveal a revolutionary strategy to find life outside Earth by analyzing patterns between planets and reducing errors that confound current science.
-
China sets up extreme weight loss camps with strict rules, daily weigh-ins, and intense workouts that divide experts and go viral on social media.
-
Humanoid robots will be tested to work at a Japanese airport, as the country faces a severe labor shortage.
-
NASA rover finds on Mars a rock with ancient water, organic matter, and a possible biological signature, and the discovery reignites the warning that the Red Planet may have harbored microbial life billions of years ago and still hold traces beyond the reach of current robots.
EBV virus affects 95% of the world’s population and can remain silent for years
EBV belongs to the herpesvirus family and can remain in the body for life. After the initial infection, it usually enters a latent state, a kind of silent mode in which it does not cause obvious symptoms in most people.
In adolescents and young adults, the virus can cause mononucleosis, a disease known to cause fever, intense fatigue, and swollen lymph nodes. In most cases, the body controls the infection, but the virus does not disappear completely.
The concern grows because EBV is associated with lymphomas, stomach cancer, and other tumors. There is also a strong relationship between viral infection and multiple sclerosis, a disease that affects the nervous system and can cause loss of strength, fatigue, and movement changes.
Mice with human genes helped create antibodies closer to those used in therapies
The strategy involved modified mice to carry human genes linked to antibody production. This does not mean that the animals have complete human DNA, but that they received specific parts capable of guiding the creation of antibodies with human characteristics.
This detail is important because antibodies very different from human ones can generate rejection or lower efficacy in treatments. By using this model, researchers sought molecules with greater potential for future use in people.
The created antibodies target EBV surface proteins. These proteins act as keys used by the virus to approach cells and initiate infection. Blocking these keys can prevent the virus from advancing.
According to ScienceDaily, a North American news portal about scientific discoveries, the advance published on April 15, 2026 highlighted antibodies capable of targeting two EBV proteins, called gp350 and gp42.
The gp350 protein helps the virus attach to the cell. Meanwhile, gp42 participates in a decisive step for EBV’s entry into B cells, which are part of the immune system and can serve as a hiding place for the virus.
In tests, the antibody targeting gp42 completely prevented infection in humanized mice exposed to EBV. Another antibody, directed at gp350, showed partial protection, which indicates that not all targets have the same weight in defense against the virus.
Blocking virus entry can protect transplant patients and immunosuppressed individuals
The most immediate impact may appear among patients who have received transplants or live with compromised immunity. In these cases, the body may have more difficulty controlling EBV, which increases the risk of viral reactivation and serious complications.
One of the threats is the uncontrolled growth of infected defense cells. In simple terms, this process can lead to lymphoproliferative diseases, which are dangerous alterations in the increase of immune system cells and can evolve into forms of lymphoma.
The possibility of using ready-made antibodies as preventive protection is interesting precisely because the action would be rapid. Instead of waiting for the body to produce defense, the person would receive molecules already prepared to recognize and block the virus.
Research is still in the pre-human testing phase and requires caution
Despite the promising result, the study is still in the pre-human testing phase. This means that the protection observed in humanized mice needs to be confirmed in people, with rigorous evaluation of safety, dose, and duration of effect.
There is also no proof that these antibodies can already prevent cancer or multiple sclerosis in humans. The link between EBV and these diseases is relevant, but transforming viral blockade into clinical prevention requires new studies.
The next step should involve initial safety tests in volunteers and then research with higher-risk groups. Only then will it be possible to measure whether the strategy truly reduces infections, reactivations, or complications associated with the virus.
Antibodies against EBV do not replace vaccines, but can create a new front of protection
The antibody approach functions as passive protection. The body receives ready-made defense, which can be useful in situations of immediate risk or when the person cannot respond well to a vaccine.
Vaccines, on the other hand, aim to train the immune system to produce its own protection. The two strategies can be complementary in the future, especially if EBV continues to be confirmed as an important piece in different diseases.
The advance reinforces a shift in focus: moving from merely treating complications to trying to stop the virus at an initial stage. This logic can alter prevention in vulnerable patients and open space for new therapies against EBV-linked diseases.
There is still a long way to go until any widespread medical application. Nevertheless, blocking the entry of the virus into cells places research at a strategic point, with the potential to change the understanding of cancer, immunity, and multiple sclerosis.
Be the first to react!